Topotecan for the treatment of recurrent or progressive central nervous system tumors - A pediatric oncology group phase II study

Richard P. Kadota, Clinton F. Stewart, Marianna Horn, John F. Kuttesch, Peter C. Burger, James L. Kepner, Larry E. Kun, Henry S. Friedman, Richard L. Heideman

Research output: Contribution to journalArticle

Abstract

Topotecan was studied as a 72 h infusion given every 3 weeks. Treatment began at a dose of 1.0 mg/m2/day and was increased to 1.25 mg/m2/day after the first 6 patients tolerated this higher dose without excessive toxicities. Eighty-eight evaluable children were accrued in 6 strata. There were no complete nor partial responses. Twenty subjects had stable disease (astrocytoma 5/11, malignant glioma 5/13, medulloblastoma 0/12, brain stem tumor 4/19, ependymoma 5/17, and miscellaneous histologies 1/16). Two patients (astrocytoma, ependymoma) completed the maximum 18 topotecan courses. The remaining 68 children developed progressive disease within 2 months. Myelosuppression was the main toxicity. Grade 4 leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 18, 32, 5, and 23 participants, respectively. It was concluded that topotecan as given according to this schedule showed insufficient activity to promote it to frontline protocol usage.

Original languageEnglish (US)
Pages (from-to)43-47
Number of pages5
JournalJournal of Neuro-Oncology
Volume43
Issue number1
DOIs
StatePublished - 1999

Fingerprint

Topotecan
Central Nervous System Neoplasms
Ependymoma
Astrocytoma
Pediatrics
Brain Stem Neoplasms
Medulloblastoma
Leukopenia
Neutropenia
Glioma
Thrombocytopenia
Anemia
Histology
Appointments and Schedules
Therapeutics

Keywords

  • Brain tumors
  • Phase II trial
  • Topoisomerase I
  • Topotecan

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Kadota, R. P., Stewart, C. F., Horn, M., Kuttesch, J. F., Burger, P. C., Kepner, J. L., ... Heideman, R. L. (1999). Topotecan for the treatment of recurrent or progressive central nervous system tumors - A pediatric oncology group phase II study. Journal of Neuro-Oncology, 43(1), 43-47. https://doi.org/10.1023/A:1006294102611

Topotecan for the treatment of recurrent or progressive central nervous system tumors - A pediatric oncology group phase II study. / Kadota, Richard P.; Stewart, Clinton F.; Horn, Marianna; Kuttesch, John F.; Burger, Peter C.; Kepner, James L.; Kun, Larry E.; Friedman, Henry S.; Heideman, Richard L.

In: Journal of Neuro-Oncology, Vol. 43, No. 1, 1999, p. 43-47.

Research output: Contribution to journalArticle

Kadota, RP, Stewart, CF, Horn, M, Kuttesch, JF, Burger, PC, Kepner, JL, Kun, LE, Friedman, HS & Heideman, RL 1999, 'Topotecan for the treatment of recurrent or progressive central nervous system tumors - A pediatric oncology group phase II study', Journal of Neuro-Oncology, vol. 43, no. 1, pp. 43-47. https://doi.org/10.1023/A:1006294102611
Kadota, Richard P. ; Stewart, Clinton F. ; Horn, Marianna ; Kuttesch, John F. ; Burger, Peter C. ; Kepner, James L. ; Kun, Larry E. ; Friedman, Henry S. ; Heideman, Richard L. / Topotecan for the treatment of recurrent or progressive central nervous system tumors - A pediatric oncology group phase II study. In: Journal of Neuro-Oncology. 1999 ; Vol. 43, No. 1. pp. 43-47.
@article{17231d6b98524b87a7ea4c9f8f0df3e6,
title = "Topotecan for the treatment of recurrent or progressive central nervous system tumors - A pediatric oncology group phase II study",
abstract = "Topotecan was studied as a 72 h infusion given every 3 weeks. Treatment began at a dose of 1.0 mg/m2/day and was increased to 1.25 mg/m2/day after the first 6 patients tolerated this higher dose without excessive toxicities. Eighty-eight evaluable children were accrued in 6 strata. There were no complete nor partial responses. Twenty subjects had stable disease (astrocytoma 5/11, malignant glioma 5/13, medulloblastoma 0/12, brain stem tumor 4/19, ependymoma 5/17, and miscellaneous histologies 1/16). Two patients (astrocytoma, ependymoma) completed the maximum 18 topotecan courses. The remaining 68 children developed progressive disease within 2 months. Myelosuppression was the main toxicity. Grade 4 leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 18, 32, 5, and 23 participants, respectively. It was concluded that topotecan as given according to this schedule showed insufficient activity to promote it to frontline protocol usage.",
keywords = "Brain tumors, Phase II trial, Topoisomerase I, Topotecan",
author = "Kadota, {Richard P.} and Stewart, {Clinton F.} and Marianna Horn and Kuttesch, {John F.} and Burger, {Peter C.} and Kepner, {James L.} and Kun, {Larry E.} and Friedman, {Henry S.} and Heideman, {Richard L.}",
year = "1999",
doi = "10.1023/A:1006294102611",
language = "English (US)",
volume = "43",
pages = "43--47",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Topotecan for the treatment of recurrent or progressive central nervous system tumors - A pediatric oncology group phase II study

AU - Kadota, Richard P.

AU - Stewart, Clinton F.

AU - Horn, Marianna

AU - Kuttesch, John F.

AU - Burger, Peter C.

AU - Kepner, James L.

AU - Kun, Larry E.

AU - Friedman, Henry S.

AU - Heideman, Richard L.

PY - 1999

Y1 - 1999

N2 - Topotecan was studied as a 72 h infusion given every 3 weeks. Treatment began at a dose of 1.0 mg/m2/day and was increased to 1.25 mg/m2/day after the first 6 patients tolerated this higher dose without excessive toxicities. Eighty-eight evaluable children were accrued in 6 strata. There were no complete nor partial responses. Twenty subjects had stable disease (astrocytoma 5/11, malignant glioma 5/13, medulloblastoma 0/12, brain stem tumor 4/19, ependymoma 5/17, and miscellaneous histologies 1/16). Two patients (astrocytoma, ependymoma) completed the maximum 18 topotecan courses. The remaining 68 children developed progressive disease within 2 months. Myelosuppression was the main toxicity. Grade 4 leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 18, 32, 5, and 23 participants, respectively. It was concluded that topotecan as given according to this schedule showed insufficient activity to promote it to frontline protocol usage.

AB - Topotecan was studied as a 72 h infusion given every 3 weeks. Treatment began at a dose of 1.0 mg/m2/day and was increased to 1.25 mg/m2/day after the first 6 patients tolerated this higher dose without excessive toxicities. Eighty-eight evaluable children were accrued in 6 strata. There were no complete nor partial responses. Twenty subjects had stable disease (astrocytoma 5/11, malignant glioma 5/13, medulloblastoma 0/12, brain stem tumor 4/19, ependymoma 5/17, and miscellaneous histologies 1/16). Two patients (astrocytoma, ependymoma) completed the maximum 18 topotecan courses. The remaining 68 children developed progressive disease within 2 months. Myelosuppression was the main toxicity. Grade 4 leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 18, 32, 5, and 23 participants, respectively. It was concluded that topotecan as given according to this schedule showed insufficient activity to promote it to frontline protocol usage.

KW - Brain tumors

KW - Phase II trial

KW - Topoisomerase I

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0032780661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032780661&partnerID=8YFLogxK

U2 - 10.1023/A:1006294102611

DO - 10.1023/A:1006294102611

M3 - Article

VL - 43

SP - 43

EP - 47

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -